polycystic%20ovarian%20syndrome
POLYCYSTIC OVARIAN SYNDROME
Polycystic ovarian syndrome (PCOS) is the accumulation of underdeveloped follicles in the ovaries due to anovulation. It is is characterized by menstrual abnormalities and clinical or biochemical features of hyperandrogenism.
It results mainly from abnormal steroidogenesis that may be caused by insulin resistance leading to hyperinsulinemia.
There is increased sensitivity to androgens and the majority of women have elevated androgen levels.
Drug Information

Indication: Type 2 DM in adult particularly in overwt patients when dietary management & exercise alone does not resul...

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. Adjunct to die...

Indication: Puregon Vial/Cartridge Women: Anovulation in women who have been unresponsive to treatment w/ clomiphene ...

Indication: Monotherapy or in combination w/ other oral antidiabetics or insulin in type 2 DM inadequately controlled by d...

Indication: NIDDM when hyperglycemia cannot be controlled by diet management, exercise or wt reduction. Monotherapy or adj...

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin...

Indication: Women of reproductive age w/ moderate to severe acne related to androgen-sensitivity (w/ or w/o seborrhea) &am...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
01 Apr 2019
Basal-bolus therapy using glargine 300 U/mL and insulin glulisine is superior to twice-daily injections of insulin degludec/aspart for glycaemic control without increasing the risk of hypoglycaemia, a new study suggests.